FERRARA, ROBERTO
FERRARA, ROBERTO
Facoltà di Medicina e Chirurgia
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors
2022-01-01 Campochiaro, C.; Farina, N.; Tomelleri, A.; Ferrara, R.; Viola, S.; Lazzari, C.; De Luca, G.; Raggi, D.; Bulotta, A.; Matucci-Cerinic, M.; Necchi, A.; Garassino, M.; Gregorc, V.; Dagna, L.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
2024-01-01 Hines, Jacobi B.; Cameron, Robert B.; Esposito, Alessandra; Kim, Leeseul; Porcu, Luca; Nuccio, Antonio; Viscardi, Giuseppe; Ferrara, Roberto; Veronesi, Giulia; Forde, Patrick M.; Taube, Janis; Vokes, Everett; Bestvina, Christine M.; Dolezal, James M.; Sacco, Matteo; Monteforte, Marta; Cascone, Tina; Garassino, Marina C.; Torri, Valter
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?
2023-01-01 Venanzi, F. M.; Bini, M.; Nuccio, A.; De Toma, A.; Lambertini, M.; Ogliari, F. R.; Oresti, S.; Vigano, M. G.; Brioschi, E.; Polignano, M.; Naldini, M. M.; Riva, S.; Ferrara, M.; Fogale, N.; Damiano, G.; Russo, V.; Reni, M.; Veronesi, G.; Foggetti, G.; Conforti, F.; Bulotta, A.; Ferrara, R.
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
2023-01-01 Nuccio, A.; Viscardi, G.; Salomone, F.; Servetto, A.; Venanzi, F. M.; Riva, S. T.; Oresti, S.; Ogliari, F. R.; Viganò, M.; Bulotta, A.; Cameron, R.; Esposito, A.; Hines, J.; Bianco, R.; Reni, M.; Cascone, T.; Garassino, M. C.; Torri, V.; Veronesi, G.; Cinquini, M.; Ferrara, R.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors | 1-gen-2022 | Campochiaro, C.; Farina, N.; Tomelleri, A.; Ferrara, R.; Viola, S.; Lazzari, C.; De Luca, G.; Raggi, D.; Bulotta, A.; Matucci-Cerinic, M.; Necchi, A.; Garassino, M.; Gregorc, V.; Dagna, L. | |
| Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC | 1-gen-2024 | Hines, Jacobi B.; Cameron, Robert B.; Esposito, Alessandra; Kim, Leeseul; Porcu, Luca; Nuccio, Antonio; Viscardi, Giuseppe; Ferrara, Roberto; Veronesi, Giulia; Forde, Patrick M.; Taube, Janis; Vokes, Everett; Bestvina, Christine M.; Dolezal, James M.; Sacco, Matteo; Monteforte, Marta; Cascone, Tina; Garassino, Marina C.; Torri, Valter | |
| Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? | 1-gen-2023 | Venanzi, F. M.; Bini, M.; Nuccio, A.; De Toma, A.; Lambertini, M.; Ogliari, F. R.; Oresti, S.; Vigano, M. G.; Brioschi, E.; Polignano, M.; Naldini, M. M.; Riva, S.; Ferrara, M.; Fogale, N.; Damiano, G.; Russo, V.; Reni, M.; Veronesi, G.; Foggetti, G.; Conforti, F.; Bulotta, A.; Ferrara, R. | |
| Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies | 1-gen-2023 | Nuccio, A.; Viscardi, G.; Salomone, F.; Servetto, A.; Venanzi, F. M.; Riva, S. T.; Oresti, S.; Ogliari, F. R.; Viganò, M.; Bulotta, A.; Cameron, R.; Esposito, A.; Hines, J.; Bianco, R.; Reni, M.; Cascone, T.; Garassino, M. C.; Torri, V.; Veronesi, G.; Cinquini, M.; Ferrara, R. |